Zoledronic acid, pravastatin ( DrugBank: Pravastatin, Zoledronic acid )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
333	ハッチンソン・ギルフォード症候群	3

333. ハッチンソン・ギルフォード症候群

---

臨床試験数 : 7 /  薬物数 : 8 - (DrugBank : 3) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 6

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00916747 (ClinicalTrials.gov)	August 2009	5/6/2009	Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria	An Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome(HGPS) and Progeroid Laminopathies	Progeria	Drug: Lonafarnib, Zoledronic Acid, and Pravastatin	Boston Children's Hospital	Schering-Plough;Merck Sharp & Dohme Corp.;Eiger BioPharmaceuticals	Active, not recruiting	N/A	N/A	All	85	Phase 2	United States
2	NCT00879034 (ClinicalTrials.gov)	March 2009	8/4/2009	A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria	A Phase II Pilot Study of Zoledronic Acid, Pravastatin, and Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies	Progeria;Hutchinson-Gilford Syndrome	Drug: Lonafarnib;Drug: Zoledronic Acid;Drug: Pravastatin	Boston Children's Hospital	Dana-Farber Cancer Institute;Brigham and Women's Hospital;Schering-Plough	Completed	N/A	N/A	All	5	Phase 2	United States
3	NCT00731016 (ClinicalTrials.gov)	October 2008	1/8/2008	Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid	Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid	Hutchinson-Gilford Progeria Syndrome	Drug: Zoledronic acid, pravastatin	Assistance Publique Hopitaux De Marseille	NULL	Completed	3 Years	N/A	Both	15	Phase 2	France